
    
      The study will enroll up to 40 pediatric, adolescent and adult Glut 1 DS participants who
      have completed the UX007G-CL201 (NCT019933186) study and, at the discretion of the Sponsor,
      additional participants from other clinical studies, investigator sponsored trials (ISTs), or
      expanded access/compassionate use treatment.
    
  